| scholarly article | Q13442814 |
| P2093 | author name string | Alexander W Pastuszak | |
| Aylin N Bilgutay | |||
| P2860 | cites work | The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets | Q35116422 |
| A Population-Based Study of Peyronie's Disease: Prevalence and Treatment Patterns in the United States | Q35450218 | ||
| Results of radiotherapy for Peyronie's disease | Q36260376 | ||
| Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix | Q36526721 | ||
| Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial | Q36734258 | ||
| Effect of botulinum toxin type a on a rat surgical wound model | Q37165762 | ||
| Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. | Q37220153 | ||
| Experimental models of Peyronie's disease. Implications for new therapies | Q37366837 | ||
| Inhibition of histone deacetylase 2 mitigates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque. | Q37437050 | ||
| Peyronie's disease following radical prostatectomy: incidence and predictors | Q37760571 | ||
| Penile plication without degloving enables effective correction of complex Peyronie's deformities | Q37988144 | ||
| EAU guidelines on penile curvature | Q38015597 | ||
| Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies | Q38078696 | ||
| High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie's disease | Q38202687 | ||
| Low testosterone has a similar prevalence among men with sexual dysfunction due to either Peyronie's disease or erectile dysfunction and does not correlate with Peyronie's disease severity | Q38315147 | ||
| Effects of botulinum toxin type A on expression of genes in keloid fibroblasts | Q38315252 | ||
| Strategies for penile prosthesis placement in Peyronie's disease and corporal fibrosis | Q38364960 | ||
| PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT. | Q38568077 | ||
| Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies | Q39035809 | ||
| Outcome analysis for conservative management of Peyronie's disease | Q39352017 | ||
| A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. | Q39383271 | ||
| Treatment of Peyronie's disease with local interferon-alpha 2b. | Q39419090 | ||
| Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience | Q39427029 | ||
| Current sexual functioning in 106 patients with Peyronie's disease treated with radiotherapy 9 years earlier | Q39433539 | ||
| Is colchicine effective in Peyronie's disease? A pilot study | Q39482557 | ||
| Sexual dysfunction: The potential of stem cell therapy for Peyronie disease | Q39517384 | ||
| Defining predictors of response to intralesional verapamil injection therapy for Peyronie's disease | Q39731742 | ||
| Responsiveness of the Peyronie's Disease Questionnaire (PDQ). | Q41460629 | ||
| Penile lengthening and widening without grafting according to a modified 'sliding' technique | Q41508675 | ||
| Lengthening shortened penis caused by Peyronie's disease using circular venous grafting and daily stretching with a vacuum erection device | Q41614254 | ||
| The effects of colchicine on a Peyronie's-like condition in an animal model | Q41665815 | ||
| The relationship between androgens, regulators of collagen metabolism, and Peyronie's disease: a case control study | Q43003220 | ||
| Evaluation of intralesional injection of verapamil in treatment of Peyronie's disease. | Q43085607 | ||
| Decorin as a new treatment alternative in Peyronie's disease: preliminary results in the rat model | Q43601232 | ||
| Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report | Q43669319 | ||
| A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome | Q43692651 | ||
| Peyronie's disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years | Q43830488 | ||
| The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. | Q43901005 | ||
| Experience with intraplaque injection of verapamil for Peyronie's disease | Q44072672 | ||
| Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease | Q44461634 | ||
| Treatment of Peyronie's Disease with Procarbazine | Q44523772 | ||
| Psychosexual Symptoms and Treatment of Peyronie's Disease Within a Collaborative Care Model | Q26826879 | ||
| Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study | Q30011016 | ||
| Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects | Q30857029 | ||
| Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship | Q33453878 | ||
| Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease | Q33642378 | ||
| Peyronie's disease: experience of local treatment with Orgotein | Q34057229 | ||
| Procarbazine (Natulan) in the treatment of Peyronie's disease | Q34057899 | ||
| Penile prosthesis implantation in the treatment of Peyronie's disease and erectile dysfunction | Q34062833 | ||
| Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study. | Q34132004 | ||
| Histone deacetylase: a potential therapeutic target for fibrotic disorders | Q34257607 | ||
| Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease | Q34292903 | ||
| Psychological impact of Peyronie's disease: a review | Q34311899 | ||
| Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study | Q34403964 | ||
| Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease | Q34422079 | ||
| Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study | Q34429388 | ||
| A case-control study on risk factors for Peyronie's disease | Q34472829 | ||
| Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease | Q34534562 | ||
| The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease | Q34619272 | ||
| Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease | Q85758154 | ||
| Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study | Q85944170 | ||
| Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study | Q87168353 | ||
| Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study | Q87360093 | ||
| L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures | Q44783709 | ||
| Proposal: trauma as the cause of the Peyronie's lesion | Q45102133 | ||
| A novel PI3K inhibitor alleviates fibrotic responses in fibroblasts derived from Peyronie's plaques | Q45336333 | ||
| Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial | Q45803932 | ||
| Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: A prospective, randomized, double-blind placebo-controlled study. | Q46005434 | ||
| Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study | Q46130680 | ||
| Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease | Q46153965 | ||
| Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study | Q46329766 | ||
| Prevalence of Peyronie's disease among patients with erectile dysfunction | Q46507650 | ||
| Lingual mucosal graft in treatment of Peyronie disease | Q46522114 | ||
| Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. | Q46600601 | ||
| Role of hyperthermia in the treatment of Peyronie's disease: a preliminary study. | Q46600990 | ||
| Peyronie’s Disease: A Study of its Natural History and Treatment with Orthovoltage Radiotherapy | Q46815482 | ||
| Risk factors for Peyronie's disease: a case-control study. | Q46936661 | ||
| Treatment of Peyronie's disease with oral pentoxifylline | Q46937612 | ||
| The treatment of Peyronie's disease with tamoxifen | Q46941711 | ||
| Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie's disease | Q47207434 | ||
| The test-retest reliability of the Peyronie's disease questionnaire | Q48059709 | ||
| Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial | Q48545304 | ||
| Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease | Q48884014 | ||
| Minimally Invasive Therapy Using Intralesional OnabotulinumtoxinA in Peyronie's Disease | Q49087219 | ||
| Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease. | Q50978859 | ||
| Intralesional verapamil injection for the treatment of Peyronie's disease. | Q51133527 | ||
| Penile prosthetic surgery for Peyronie's disease: defining the need for intraoperative adjuvant maneuvers. | Q51285496 | ||
| The chronology of depression and distress in men with Peyronie's disease. | Q51889728 | ||
| Penile deviation--our therapeutic concept | Q53019990 | ||
| Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire. | Q53116615 | ||
| Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. | Q53118860 | ||
| A new, innovative, lengthening surgical procedure for Peyronie's disease by penile prosthesis implantation with double dorsal-ventral patch graft: the "sliding technique". | Q53133398 | ||
| Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study. | Q53185325 | ||
| A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. | Q53193957 | ||
| Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. | Q53230701 | ||
| Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. | Q53257180 | ||
| [Effect of botulinum toxin type A injection on hypertrophic scar in rabbit ear model]. | Q53363086 | ||
| An alternative non-invasive treatment for Peyronie's disease. | Q53595918 | ||
| Tamoxifen versus placebo in the treatment of Peyronie's disease. | Q55033437 | ||
| Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease | Q56995395 | ||
| Surgical treatment of Peyronie's disease by plaque incision and grafting with buccal mucosa | Q57155396 | ||
| Simultaneous Total Corporal Reconstruction and Implantation of a Penile Prosthesis in Patients with Erectile Dysfunction and Severe Fibrosis of the Corpora Cavernosa | Q60229492 | ||
| Simultaneous Penile Lengthening and Penile Prosthesis Implantation in Patients with Peyronie's Disease, Refractory Erectile Dysfunction, and Severe Penile Shortening | Q60229493 | ||
| ORIGINAL RESEARCH—PEYRONIE'S DISEASE: Use of Penile Extender Device in the Treatment of Penile Curvature as a Result of Peyronie's Disease. Results of a Phase II Prospective Study | Q62660594 | ||
| Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie's disease | Q64378178 | ||
| Induration penis plastica. Experience of treatment with procarbazine Natulan | Q67456885 | ||
| Orgotein, a new drug for the treatment of Peyronie's disease | Q70238800 | ||
| Treatment of Peyronie's disease with local interferon-alpha 2b | Q70824459 | ||
| Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens | Q72112799 | ||
| Intralesional recombinant interferon alpha-2b in Peyronie's disease | Q73092160 | ||
| Intralesional interferon in the treatment of Peyronie's disease: a pilot study | Q73095964 | ||
| Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome | Q73112619 | ||
| Patient and partner satisfaction and long-term results after surgical treatment for Peyronie's disease | Q73599123 | ||
| Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging | Q73957484 | ||
| Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study | Q74544970 | ||
| Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study | Q76372661 | ||
| The prevalence of Peyronie's disease: results of a large survey | Q77756733 | ||
| A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease | Q78144121 | ||
| Stimulation of collagen production in an in vitro model for Peyronie's disease | Q78193334 | ||
| Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba) | Q78663002 | ||
| Surgical treatment of Peyronie's disease: a single center experience with 145 patients | Q80234384 | ||
| Intralesional verapamil prevents the progression of Peyronie's disease | Q80485567 | ||
| Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study | Q80974595 | ||
| Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature | Q82237366 | ||
| The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease | Q82304763 | ||
| Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study | Q83039500 | ||
| Factors affecting the degree of penile deformity in Peyronie disease: an analysis of 1001 patients | Q83201949 | ||
| Does testosterone deficiency exaggerate the clinical symptoms of Peyronie's disease? | Q84869341 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Peyronie's disease | Q874586 |
| P304 | page(s) | 6-14 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Indian Journal of Urology | Q6020825 |
| P1476 | title | Peyronie's disease: What's around the bend? | |
| P478 | volume | 32 |
| Q89999368 | Anti-fibrotic effect of mycophenolate mofetil on Peyronie's disease experimentally induced with TGF-β |
| Q26746145 | Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up |
| Q55349667 | Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie's disease. |
Search more.